Seeking Alpha
View as an RSS Feed

Smith On Stocks  

View Smith On Stocks' Comments BY TICKER:

Latest  |  Highest rated
  • ImmunoCellular: Thoughts On Management's Plan To Move ICT-107 Into Phase 3 [View article]
    I will listen, but I seldom publish on Seeking Alpha. My comments if any will be on my website
    Nov 24, 2015. 08:32 AM | Likes Like |Link to Comment
  • KaloBios: Martin Shkreli Vs. The Rest Of The World [View article]
    I readily admit that I don't understand it, but your explanation is not believable. I think we are seeing the effect of high frequency trading in dark pools.
    Nov 23, 2015. 11:24 AM | Likes Like |Link to Comment
  • KaloBios: Martin Shkreli Vs. The Rest Of The World [View article]
    Help me to understand how the trading volume in the last five trading days has been 38.5 million shares.
    Nov 23, 2015. 08:08 AM | 1 Like Like |Link to Comment
  • Discovery Laboratories: Results For Phase 2a Trial Are Quite Encouraging; Why Then Did The Stock Crash  [View instapost]
    Phase 2b results on a 250 patient, randomized trial will complete enrollment in mid-2016 and report topline results in 4Q, 2016.
    Nov 14, 2015. 08:30 AM | Likes Like |Link to Comment
  • Update: Aerosurf P2A Readout Shows Mixed Results, But Investment Case Remains [View article]
    Here is my take on DSCO.
    Nov 14, 2015. 07:55 AM | Likes Like |Link to Comment
  • The Northwest Biotherapeutics House Of Cards Is Ready To Collapse [View article]
    We are all trying to figure out who Five Phase is. A subscriber to my website sent me the following comment on the authors of this Seeking Alpha article.

    Phase V doesn't want to reveal their identity

    If you look up their website registration you see...


    Registry Domain ID: 1874592735_DOMAIN_COM-... Registrar WHOIS Server: Registrar URL: Update Date: 2015-09-08T18:21:23Z Creation Date: 2014-09-07T08:37:54Z Registrar Registration Expiration Date: 2017-09-07T08:37:54Z

    Registrar:, LLC

    Registrar IANA ID: 146

    Registrar Abuse Contact Email: Registrar Abuse Contact Phone: +1.4806242505 Domain Status: ok Registry Registrant ID:

    Registrant Name: Registration Private

    Registrant Organization: Domains By Proxy, LLC Registrant Street: Registrant Street: 14747 N Northsight Blvd Suite 111, PMB 309 Registrant City: Scottsdale Registrant State/Province: Arizona Registrant Postal Code: 85260 Registrant Country: United States

    They have gone to great lengths to hide who they are in fear that they would get sued for spreading misinformation.
    Oct 29, 2015. 10:42 AM | 21 Likes Like |Link to Comment
  • The Northwest Biotherapeutics House Of Cards Is Ready To Collapse [View article]
    There is one inherent contradiction that runs through all the short attacks on NWBO in the approximate eleven such articles published on Seeking Alpha over the last two years or so. Except for one, all were written by anonymous short sellers. They make two essential points. The first is that the science behind DCVax-L and DCVax Direct is flawed and there is no chance that the products will be effective. I would remind people that this technology is based on the role of the dendritic cell in activating the active and innate immune system. This won their discoverers the Nobel Prize in 2011. Secondly, there has already been one product approved that uses dendritic cell vaccine technology. That was Provenge which was approved on the basis of a 4.5 month improvement in median overall survival in metastatic colon cancer (4.5 months is considered by key opinion leaders to be a significant advance). To me, this suggests that dendritic cell cancer vaccines like DCVax-L and DCVax Direct are based on solid science. I for one feel that cancer vaccines could be a major advance in the treatment of cancer and dendritic cell cancer vaccines are an extremely logical approach.
    The next point that the short selling articles make is that Linda Powers has a major stake in Cognate and Northwest; Cognate is the manufacturer of DCVax-L and DCVax Direct. Northwest in large part because of constant short selling and coordinated attack articles like this has been cash starved. If Cognate had demanded cash for manufacturing these products, NWBO would have been unable to continue the trials. Cognate instead has accepted over 20 million shares of NWBO for its services. The shorts on the one hand tell us that this stock is worthless and then say that this is transferring wealth away for NAWBO shareholders. There is no question that the DCVax-L phase 3 trial would have been suspended and the DCVax Direct trial would never have taken place without Cognate accepting stock in lieu of cash. I think that all NWBO shareholders should thank Cognate for its role in keeping the trials going. If the shorts are correct, Cognate has accepted worthless stock of NWBO in lieu of $80 million or more of cash. Hmmmm.
    This is an article like almost all the other negative Seeking Alpha articles is written by anonymous authors who are short the stock. This article alleges criminal misconduct on the part of NWBO management. This is an extremely serious charge and I believe that we entitled to know who the authors are. It is also troubling that they are short before the article was published. This is consistent with stock manipulation. I think that Seeking Alpha should demans that all authors publish under their real names. The information in this article has large components taken from previous Seeking Alpha articles. At its heart there is nothing new. For those of you who are perplexed by this unrelenting attack on Northwest Biotherapeutics, I suggest that you look at three links. . and and


    Oct 29, 2015. 09:29 AM | 35 Likes Like |Link to Comment
  • Northwest Bio secures $30M in new capital [View news story]
    Here is my take.
    Oct 21, 2015. 02:32 PM | 9 Likes Like |Link to Comment
  • Researchers put positive spin on effect of Neuralstem's NSI-566 in ALS patients; shares down 5% [View news story]
    I found it a bit strange that Seeking Alpha wrote this referenced article on Genervon, a small private company, as their articles almost exclusively deal with publicly traded companies. It was also surprising that this article was written by a Seeking Alpha editor, not an external contributing author. The article appeared coincident with significant shorting of Neuralstem.
    Sep 29, 2015. 02:40 PM | 6 Likes Like |Link to Comment
  • Researchers put positive spin on effect of Neuralstem's NSI-566 in ALS patients; shares down 5% [View news story]
    I think that the word spin is pejorative and inappropriate in this case. Spin suggests that the data is presented in a way that makes the data appear better than it actually is. The lead presenter Eva Feldman. She is a distingusihed ALS researcher and past president of the American Neurological Association. What reason do you have for suggesting that she is spinning results? You have also just reprinted the press release without any analysis of the information. For an analysis of the information in this press release, please see this report.
    Sep 29, 2015. 10:40 AM | 17 Likes Like |Link to Comment
  • Northwest Bio: FDA Panel Recommendation On Amgen's Cancer Vaccine Is Significant For DCVax-L And DCVax Direct [View article]
    The naked shorting campaign against NWBO was a criminal enterprise. Check this link.

    There are 10 million acknowledge shorts by NASDAQ, but there may be 10 to 40 million naked shorts.
    Jul 17, 2015. 08:18 AM | 3 Likes Like |Link to Comment
  • ImmunoCellular to proceed with ICT-107 Phase 3 despite failing Phase 2 [View news story]
    Jul 15, 2015. 08:28 AM | Likes Like |Link to Comment
  • Bristol-Myers Squibb Is An Overvalued Company In Quite An Expensive Sector [View article]
    You are looking in the rear view mirror. BMY's leadership position in immuno-oncology will produce exceptional growth over the next five years. Opdivo alone might reach $5 billion in 2020 with Eliquis not far behind. This is off of a comparatively small pharmaceutical revenue base of $12 billion in 2014. Acuisitions and internally developed or licensed new products could also produce very significant revenues. This is my top pick among the big biopharm companies for the 2015 to 2020 timeframe.
    Jun 17, 2015. 01:44 PM | 5 Likes Like |Link to Comment
  • Discovery Laboratories: Surfaxin Launch Has Been Slow, But Clinical Trials Of Aerosurf Are Beginning At Last [View article]
    I am writing a report that will be published on my website withing two weeks. The stock is down in anticipation of an equity offering. Your assessment is the same as mine.
    May 19, 2015. 08:24 AM | Likes Like |Link to Comment
  • Discovery Laboratories: Collaboration With Battelle Is Validation Of Aerosurf's Potential By A Sophisticated Third Party [View article]
    The data on the phase 2 a trial must be viewed in the context that it was a single dose trial whose primary goal was to determine if the Aerosurf can be safely delivered as a single dose. The answer is yes and that is a positive. There were signals of efficacy based on lowering of FiO2 and CO2 in the twelve hours after administration. These need to be conformed in phase 2b. Based on this data, the results were quite encouraging. The stock is getting creamed in anticipation of an offering.
    May 15, 2015. 02:36 PM | Likes Like |Link to Comment